Life-Changing Medicines.
Redefining Possibilities.
patient story
Journey to Diagnosis
Narcolepsy is a condition that is often misunderstood, overlooked and underdiagnosed. Many people will write off excessive daytime sleepiness in teenagers because it is assumed teenagers want to sleep more often. Sam lived more than a decade experiencing symptoms of narcolepsy without a diagnosis.
Sam’s Story
Our science
Changing AML Treatment Landscape
We’re committed to developing life-changing medicines that can redefine the possibilities for life after a cancer diagnosis — in particular for patients with certain types of secondary acute myeloid leukemia (AML).
Learn More
News and Events
February 14, 2019
Jazz Pharmaceuticals Announces Appointment of Anne O’Riordan to its Board of Directors
February 12, 2019
Jazz Pharmaceuticals to Report 2018 Fourth Quarter and Full Year Financial Results on February 26, 2019
January 3, 2019
Jazz Pharmaceuticals and Codiak BioSciences Announce Strategic Collaboration to Research, Develop and Commercialize Engineered Exosomes to Create Therapies for Hard-to-Treat Cancers
#JPM2019
We’re a company that develops life-changing medicines for people with limited or no options, so they can live their lives more fully.
See all News
Jazz Pipeline
PRE-CLINICAL
Oxybate
once-nightly dosing
CombiPlex
Solid tumors

CombiPlex
Hematological malignancies

Asparaginase
ALL/other hematological malignancies
Recombinant pegaspargase
Hematological
malignancies
Defibrotide
Exploratory activities

Exosome NRAS
Hematologic malignancies§

Exosome STAT3
Hematologic malignancies§

Exosome candidates
Solid tumors/Hematologic malignancies§

PHASE 1
CPX-351 + gemtuzumab
R/R AML or HMA Failure
MDS* (ages ≥18)

CPX-351 + venetoclax
Low intensity dosing for unfit AML†

IMGN779
R/R CD33+ AML‖

IMGN632
CD123+ hematological malignancies‖

PHASE 2
Solriamfetol
EDS in Parkinson’s disease
Defibrotide
Prevention of acute GvHD
Defibrotide
Treatment of TA-TMA†
Defibrotide
Prevention of CAR-T associated neurotoxicity†

CPX-351 + venetoclax
de novo or R/R AML*

CPX-351
MDS**†

CPX-351
R/R AML**

PHASE 3
JZP-258
Cataplexy & EDS in narcolepsy

JZP-258
idiopathic hypersomnia

Defibrotide
Prevention of VOD

CPX-351
AML or HR-MDS (AML19) (ages 18-60)**‡

CPX-351
AML or HR-MDS (AML18) (ages ≥60)**‡

REGULATORY
Solriamfetol EU
EDS in OSA or narcolepsy
Solriamfetol U.S.
EDS in OSA and narcolepsy

Sleep
Hematology / Oncology
Opt-in Opportunity
*Jazz & MD Anderson Cancer Center Study
** Key Cooperative Group Study
† Planned
‡Study Sponsor – Cardiff University
§Jazz & Codiak BioSciences collaboration
‖ Jazz & ImmunoGen collaboration

Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.
More About Jazz
Living Our Values

Careers at Jazz

Clinical Trials

Learn More

By unlocking biopharmaceutical discoveries to develop novel medicines, we are giving thousands of people around the world the opportunity to redefine what’s possible.
Our Medicines